Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis c

Pharmacopsychiatry

Volumn 47, Issue 6, 2014, Pages 195-201

  Evon, D M ^a   Esserman, D E ^b   Howell, M A ^c   Ruffin, R A ^a,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c United Therapeutics Corporation   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

Author keywords

depression; hepatitis C; interferon; liver disease patients; pharmacokinetics

Indexed keywords

ANTIDEPRESSANT AGENT; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; EVALUATION STUDY; EXPLORATORY RESEARCH; FEMALE; GENDER; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; SOCIAL SUPPORT; STEADY STATE; TREATMENT RESPONSE; AREA UNDER THE CURVE; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; HEPATITIS C, CHRONIC; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SELF REPORT; SENSITIVITY AND SPECIFICITY; TIME FACTOR; UNITED STATES;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PSYCHIATRIC STATUS RATING SCALES; RECOMBINANT PROTEINS; SELF REPORT; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UNITED STATES;

EID: 84906940623     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0034-1385929     Document Type: Article

References (40)

1. Fried M. W., Shiffman M. L., Reddy K. R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med: 2002; 347 975 982
2. Poordad F., McCone J., Bacon B. R. et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine: 2011; 364 1195 1206
3. Jacobson I. M., McHutchison J. G., Dusheiko G. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med: 2011; 364 2405 2416
4. Fried M. W. Side effects of therapy of hepatitis C and their management. Hepatology: 2002; 36 S237 S244 (Pubitemid 35253486)
5. McGowan C. E., Monis A., Bacon B. R. et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology: 2013; 57 1325 1332
6. Ford N., Singh K., Cooke G. S. et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America: 2012; 54 1465 1472
7. Raison C. L., Borisov A. S., Broadwell S. D. et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry: 2005; 66 41 48
8. Evon D. M., Verma A., Simpson K. et al. Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre. Aliment Pharmacol Ther: 2008; 27 1071 1080 (Pubitemid 351614879)
9. Schafer A., Wittchen H. U., Seufert J. et al. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int J Methods Psychiatr Res: 2007; 16 186 201 (Pubitemid 351150050)
10. Dieperink E., Willenbring M., Ho S. B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry: 2000; 157 867 876 (Pubitemid 30412335)
11. Wichers M., Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol: 2002; 5 375 388 (Pubitemid 35470357)
12. Evon D. M., Ramcharran D., Belle S. H. et al. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol: 2009; 104 2949 2958
13. Wichers M. C., Koek G. H., Robaeys G. et al. Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol Med: 2005; 35 433 441 (Pubitemid 40372481)
14. Maddrey W. C. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis: 1999; 19 01 67 75
15. Evon D. M., Verma A., Dougherty K. A. et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci: 2007; 52 3251 3258 (Pubitemid 47512531)
16. Foster G. R. Review article: pegylated interferons: chemical and clinical differences. Alimentary pharmacology & therapeutics: 2004; 20 825 830 (Pubitemid 39424889)
17. Motzer R. J., Rakhit A., Ginsberg M. et al. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology: 2001; 19 1312 1319 (Pubitemid 32202535)
18. Talpaz M., Rakhit A., Rittweger K. et al. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clinical cancer research: an official journal of the American Association for Cancer Research: 2005; 11 6247 6255 (Pubitemid 41262955)
19. Silva M., Poo J., Wagner F. et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol: 2006; 45 204 213
20. Bressler B., Wang K., Grippo J. F. et al. Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). British journal of clinical pharmacology: 2009; 67 280 287
21. Dieperink E., Ho S. B., Thuras P. et al. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics: 2003; 44 104 112 (Pubitemid 36241123)
22. Hauser P., Khosla J., Aurora H. et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry: 2002; 7 942 947 (Pubitemid 35333048)
23. Bonaccorso S., Marino V., Puzella A. et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol: 2002; 22 86 90 (Pubitemid 34101297)
24. Wichers M. C., Kenis G., Leue C. et al. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry: 2006; 60 77 79
25. Prather A. A., Rabinovitz M., Pollock B. G. et al. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain, behavior, and immunity: 2009; 23 1109 1116
26. Wichers M. C., Kenis G., Koek G. H. et al. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res: 2007; 62 207 214 (Pubitemid 46161588)
27. Radloff L. S. The CES-D Scale: A self-report depression scale for research in the general population. Applied Psychological Measurement: 1977; 1 385 401
28. Conjeevaram H. S., Fried M. W., Jeffers L. J. et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology: 2006; 131 470 477 (Pubitemid 44142464)
29. Raison C. L., Demetrashvili M., Capuron L. et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs: 2005; 19 105 123 (Pubitemid 40321763)
30. Bodenheimer H. C. Jr, Lindsay K. L., Davis G. L. et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology: 1997; 26 473 477 (Pubitemid 27328328)
31. Evon D. M., Esserman D. A., Bonner J. E. et al. Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence. J Viral Hepat: 2013; 20 536 549
32. Howell C. D., Dowling T. C., Paul M. et al. Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol: 2008; 6 575 583
33. Clark C. H., Mahoney J. S., Clark D. J. et al. Screening for depression in a hepatitis C population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D). J Adv Nurs: 2002; 40 361 369
34. Yeh S. Using Trapezoidal rule for the area under the curve calculation. Paper presentation 229-27 presented at the SAS SUGI 17 Conference: 2002; Florida
35. Pegasys package insert Nutley N. J. Hoffman-La Roche, Inc: 2002; http://www.accessdata.fda.gov/drugsatfda-docs/label/2002/pegihof101602lb.htm
36. Jen J. F., Glue P., Ezzet F. et al. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clinical pharmacology and therapeutics: 2001; 69 407 421 (Pubitemid 32554546)
37. Raison C. L., Dantzer R., Kelley K. W. et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry: 2010; 15 393 403
38. Raison C. L., Borisov A. S., Majer M. et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biological psychiatry: 2009; 65 296 303
39. Pierucci-Lagha A., Covault J., Bonkovsky H. L. et al. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics: 2010; 51 137 148
40. Lotrich F. E., Ferrell R. E., Rabinovitz M. et al. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biological psychiatry: 2009; 65 344 348